7. Abaxis ( ABAX) develops, manufactures, markets and sells portable blood analysis systems for use in any human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. The company has two segments: the medical market and the veterinary market.

The company is expected to report its fourth quarter and full year 2011 results on Apr. 28. Total revenue is forecast to increase 8% to $36.4 million from $33.7 million in the year-ago quarter. Moreover, earnings are likely to surge 35% to $3.6 million or 16 cents per share from $2.6 million or 12 cents per share reported during fourth quarter 2010.

For full year 2011, earnings are forecast to increase 13.4% to $14.8 million or 65 cents per share on revenue of $142.8 million compared to $13 million or 58 cents per share on revenue of $124.6 million reported during 2010.

During Feb. 2011, the company announced a $2.8 million equity investment in Scandinavian Micro Biodevices APS (SMB), a privately-held developer and manufacturer of point-of-care diagnostic products for veterinary use.

Of the seven analysts covering the stock, 57% recommend it a buy, while the remaining rate a hold. There are no sell ratings on the stock. On average, analysts expect an upside of 6.3% to $30.8 in value from current levels. Analysts at Zacks Investment Research recently reiterated a neutral rating on the stock maintaining a price target of $30.

If you liked this article you might like

Shanda Goes Active on Community Health

Pressure Mounts at Community Health as Liquidity Concerns Grow

These 6 Healthcare Stocks Are Set to Be Tops in Their Field, Jefferies Says

Almost Family (AFAM) Weak On High Volume

Today's Strong And Under The Radar Stock: Almost Family (AFAM)